This study focuses on people with focal onset seizures, a type of epilepsy where seizures begin in one specific area of the brain. The research will test a medication called SPN-817 (also known as Huperzine A) in the form of oral capsules to determine if it can help control seizures in adults who have not responded well to other anti-seizure treatments.
The purpose of this research is to evaluate how well SPN-817 works as a treatment for adults with focal onset seizures, and to assess its safety and how well patients tolerate it. During the study, participants will receive either SPN-817 or placebo while continuing to take their current anti-seizure medications.
The treatment will involve taking capsules by mouth daily for several months. The medication dose may be adjusted during the initial period of the study, followed by a maintenance period where the dose remains stable. Throughout the study, participants will need to keep track of their seizures using an electronic diary and attend regular check-ups where their health will be monitored through various assessments.
Bulgaria 
Hungary 
Poland 
